Evotec enters multiple target drug discovery collaboration with Shionogi

Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd. (Tokyo and Osaka Stock Exchanges:4507), to identify small molecule modulators of various protein-protein interaction targets.

Evotec will apply its proprietary and integrated fragment-based drug discovery platform, EVOlution™ to the programme. The key benefit of this platform for the selection of target-specific strategies is its versatility, combining biochemical and biophysical techniques including nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography. Within this collaboration, EVOlution™ will be used to investigate protein-protein interactions on targets selected by Shionogi.

Dr Mario Polywka, COO of Evotec stated: "We are extremely pleased that Shionogi has decided to undertake these projects with Evotec. Our proprietary fragment-based drug discovery platform has shown that it adds significant value to our partner's programmes and we look forward to supporting Shionogi in finding novel treatments for inflammation and infectious diseases."

No financial details are disclosed.

SOURCE Evotec AG

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery